· 1d
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
· 1d
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
· 1d
Johnson & Johnson: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,
· 9h · on MSN
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
· 1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,
· 1d
FDA approves first-of-its-kind nasal spray for severe depression
Some results have been hidden because they may be inaccessible to you
Show inaccessible results